Zeleciment Basivarsen Targets the Underlying Cause of DM1 to Enable Functional Improvement in the Phase I/II ACHIEVE Trial (S7.001)
Shauna Andersson, Guillaume Bassez, Jordi Díaz‐Manera, James; id_orcid 0000-0002-9230-4137 Lilleker et autres
Determine the safety and efficacy of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in adults with myotonic dystrophy type 1 (DM1) in the Phase 1/2 ACHIEVE trial (NCT05481879).
us, fr, gb, nl, it, nz, de (code pays fourni par la source)